In short
This article discusses ongoing clinical trials for a novel gene therapy treatment targeting Mucopolysaccharidosis type IIIA, also known as Sanfilippo A syndrome. The therapy uses an adeno-associated viral vector serotype 9 containing the human sulfamidase gene (AAV9-CAG-coh-SGSH) to potentially address the underlying genetic cause of this rare metabolic disorder. The trials aim to evaluate the safety, tolerability, and initial efficacy of this innovative approach in children with Sanfilippo A syndrome.
At a glance
- Study Type
- Phase I/II clinical trial
- Condition
- Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)
- Intervention
- Adeno-associated viral vector serotype 9 containing human sulfamidase gene (AAV9-CAG-coh-SGSH)
- Administration
- Intracerebroventricular (ICV) injection
- Primary Objectives
- Safety, tolerability, and immune response assessment
- Secondary Objectives
- Initial efficacy, pharmacodynamic profile, biomarker evaluation
- Key Eligibility
- Children aged 2+ with confirmed MPSIIIA, specific adaptive behavior scores, not wheelchair-dependent
- Primary Endpoints
- Physical exams, blood tests, immune response, MRI, hepatic ultrasonography
- Secondary Endpoints
- Enzyme activity, heparan sulfate levels, neurobehavioral assessments, quality of life measures
What is AAV9-hSGSH?
AAV9-hSGSH, also known as AAV9-CAG-coh-SGSH, is an investigational medicinal product being studied for the treatment of Sanfilippo A Syndrome. This product is classified as a gene therapy, which means it aims to treat a disease by introducing genetic material into a patient's cells.
The full name of this therapy is Adeno-Associated Viral Vector Serotype 9 Containing the Human Sulfamidase Gene. Let's break this down:
- Adeno-Associated Viral Vector: This is a harmless virus that has been modified to carry genetic material into cells.
- Serotype 9: This refers to a specific type of the virus that is good at reaching brain cells.
- Human Sulfamidase Gene: This is the healthy gene that the therapy aims to deliver to patients' cells.
Target Condition: Sanfilippo A Syndrome
AAV9-hSGSH is being developed to treat Mucopolysaccharidosis type IIIA, also known as Sanfilippo A Syndrome. This is a rare genetic disorder that primarily affects the brain and spinal cord. Children with this condition lack an enzyme called sulfamidase, which leads to the buildup of toxic substances in their cells, causing progressive brain damage.
How AAV9-hSGSH Works
The therapy works by delivering a healthy copy of the SGSH gene, which provides instructions for making the sulfamidase enzyme, directly into the brain. The goal is for the brain cells to use this new gene to produce the missing enzyme, potentially slowing or stopping the progression of the disease.
Clinical Trial Details
A clinical trial is currently underway to test the safety and initial effectiveness of AAV9-hSGSH. This is a Phase I/II trial, which means it's one of the earliest stages of testing in humans. The main features of this trial include:
- The therapy is administered directly into the fluid surrounding the brain (intracerebroventricular or ICV administration).
- Patients receive a single dose of the treatment.
- The study will test three different dose levels in different groups of patients.
Eligibility Criteria
The trial has specific criteria for who can participate. Some key points include:
- Children aged 2 years or older
- Confirmed diagnosis of Sanfilippo A Syndrome
- Onset of symptoms before 6 years of age
- Ability to walk independently
- No severe sensory deficits (like blindness or severe deafness)
There are also several exclusion criteria, such as having antibodies against the viral vector used in the therapy or having other significant medical conditions.
Study Objectives
The main goals of this clinical trial are:
- To determine if AAV9-hSGSH is safe and well-tolerated by patients
- To assess how the body responds to the therapy, including the immune response
- To look for early signs of effectiveness in treating Sanfilippo A Syndrome
- To determine the best dose for future studies
Assessment Methods
The study will use various methods to evaluate the therapy's effects, including:
- Physical and neurological examinations
- Blood and urine tests
- Brain imaging (MRI)
- Tests of cognitive and adaptive function
- Quality of life assessments
- Sleep studies
Potential Benefits and Considerations
While AAV9-hSGSH shows promise, it's important to remember that this is still an experimental treatment. Potential benefits could include slowing or stopping the progression of Sanfilippo A Syndrome, but there may also be risks and side effects that are not yet known. The clinical trial aims to better understand both the benefits and risks of this therapy.
For families affected by Sanfilippo A Syndrome, this research represents hope for a potential treatment for this currently incurable condition. However, it's crucial to discuss any participation in clinical trials with healthcare providers and to understand that results are not guaranteed.